Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cartin-Ceba, Rodrigo, Halank, Michael, Ghofrani, Hossein-Ardeschir, Humbert, Marc, Mattson, John, Fritsch, Arno, Krowka, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987907/
https://www.ncbi.nlm.nih.gov/pubmed/29565224
http://dx.doi.org/10.1177/2045894018769305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987907/
https://www.ncbi.nlm.nih.gov/pubmed/29565224
http://dx.doi.org/10.1177/2045894018769305

Ejemplares similares